Trial Profile
A Phase 3, Controlled, Open-label, Randomized Study of RRx-001 Administered Sequentially With a Platinum Doublet or a Platinum Doublet in Third-Line or Beyond Small Cell Lung Cancer
Status:
Discontinued
Phase of Trial:
Phase III
Latest Information Update: 28 Mar 2024
Price :
$35
*
At a glance
- Drugs Nibrozetone (Primary) ; Carboplatin; Cisplatin; Etoposide
- Indications Carcinoma; Small cell lung cancer
- Focus Registrational; Therapeutic Use
- Acronyms REPLATINUM
- Sponsors EpicentRx
- 21 Mar 2023 According to an EpicentRx media release, data from this study will discussed in review of the NLRP3 Inflammasome Inhibitor RRx-001 Published in the Prestigious Scientific Journal, Drugs.
- 10 Nov 2022 According to an EpicentRx media release, data from the trial will be presented at the 4th Inflammasome Therapeutics Summit.
- 30 Sep 2022 Status changed from active, no longer recruiting to discontinued as RRx-001 will be studied under a new global, phase 3 clinical trial.